Abstract:Objective: To investigate the current trend of breast cancer neoadjuvant therapy and provide reference for the improvement of breast cancer clinical guideline in the future. Methods: Questionnaires of cross-sectional survey were sent to 110 hospitals (breast cancer surgery quantity surpassing 200) between July 2018 and September 2018. The stages and subtypes, therapeutic regimen, treatment assession, operation choice and preforming of patients underwent neoadjuvant therapy were recorded. Results: Neoadjuvant treatment has been performed in all of the 110 hospitals. The total number of breast patients underwent neoadjuvant therapy was about 14 550 (17.0% in surgical patients) in 2017. For all of the neoadjuvant patients, the proportion of stageⅡ patients was less than 30% in 81 hospitals, and the proportion of stage Ⅲ was more than 50% in 84 hospitals. The numbers of estrogen receptor (ER) (+ )/human epidermal growth factor receptor-2 (HER-2) (-), ER (-)/HER-2 (+ ) and triple negative subtype breast cancer patients were 3 550 (24.4%), 6 024 (41.4%) and 4 991 (34.3%), respectively. Patient's scruples of relatively delayed operation and weak will of breast conservation after neoadjuvant therapy were the majority reasons for neoadjuvant therapy restriction. Anthracycline followed by taxane was the most usual neoadjuvant therapeutic regimens in 53.6% hospitals, and anthracycline plus taxane was the first choice in 42.7% hospitals. Chemotherapy with targeting therapy was recommended to HER-2 positive neoadjuvant patients in 80.9% hospitals. To assess treatment outcome of neoadjuvant treatment, 42.7% hospitals used MRI in more than 50% patients while the usage rate of MRI was less than 20% in 37.3% hospitals. The proportions of hospital using repeat-marking, tattoo and metal clip as the first method to identify the primary tumor region and lymph nodes were 60.0%, 29.1% and 10.9%, respectively. Breast-conservation rate after neoadjuvant therapy was less than 20% in 87.3% hospitals. Conclusions: Neoadjuvant therapy for breast cancer is widely performed in most hospitals in China, while the proportion of neoadjuvant treatment in patients with operable breast cancer is still low. Meanwhile, the idea of achieving de-escalation operation through neoadjuvant treatment is not promoted and the therapeutic evaluation method of neoadjuvant treatment needs further studies to improve.

Clinical practice guidelines for neoadjuvant therapy in patients with early-stage breast cancer: Chinese Society of Breast Surgery practice guidelines 2022

Clinical practice guidelines for diagnosis and treatment of invasive breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

The Chinese Guidelines for Neoadjuvant Therapy of Pancreatic Cancer (2020)

Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2022

Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024

Introduction to the Key Contents of the Chinese Society of Breast Surgery Practice Guideline 2021

To establish high-quality clinical practice guidelines and promote the standardization of diagnosis and treatment of breast disease in China

Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)

[Current Trend of Breast Cancer Neoadjuvant Treatment in China: a Cross-Sectional Study].

Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022

[Guidelines for clinical diagnosis and treatment of advanced triple negative breast cancer in China（2024 edition）]

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

Chinese National Clinical Practice Guidelines on the Prevention, Diagnosis, and Treatment of Early Gastric Cancer

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Chinese national clinical practice guidelines on prevention, diagnosis and treatment of early colorectal cancer

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

Guidelines for the Diagnosis and Treatment of Pancreatic Cancer in China (2021)

Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

Clinical Practice Guidelines in Breast Cancer by Chinese Anti-Cancer Association (2015 version):interpretation of updates in terms of systemic treatment

Clinical practice guidelines for ductal carcinoma in situ: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China